Introduction And Objective: A limitation to the widespread use of primary angioplasty is delayed reperfusion. Most current data are from clinical trials and there is little information about the use of primary angioplasty in clinical practice. The objective of this study was to analyze the duration of each stage leading to primary angioplasty in a hospital where it is the treatment of choice for acute myocardial infarction.
Patients And Method: Prospective observational study of patients admitted to our hospital from April 2000 to August 2001 for acute myocardial infarction with an indication for reperfusion. The time intervals from onset of symptoms until the end of angioplasty were analyzed.
Results: Primary angioplasty was performed in 201 of 218 patients with an indication for reperfusion (92%). Median values (percentiles 25-75) were: Time 1 (onset of symptoms-hospital arrival): 91 (50-150) minutes. Time 2 (hospital arrival-call to interventional team): 20 (10-49) minutes. Time 3: (call to interventional team-team arrival): 15 (0-20) minutes. Time 4: (team arrival patient arrival at the catheterization laboratory): 10 (5-15) minutes. Time 5 (patient arrival-opening of coronary artery): 20 (15-30) minutes. Time 6 (opening of coronary artery-TIMI III flow): 10 (0-25) minutes.
Conclusions: The most time-consuming stage in primary angioplasty was from the onset of symptoms until patient arrival at the hospital (Time 1). Inside the hospital, the most time-consuming stage was the diagnosis and decision to perform angioplasty (Time 2). The rates of primary angioplasty could be increased if delays in reperfusion were reduced with respect to those considered acceptable in current practice guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0300-8932(02)76667-0 | DOI Listing |
Cardiovasc Intervent Radiol
January 2025
Scientific Affairs, Becton Dickinson and Company, Tulsa, USA.
Purpose: The AVeNEW Post-Approval Study (AVeNEW PAS) follows upon results from the AVeNEW IDE clinical trial and was designed to provide additional clinical evidence of safety and effectiveness using the Covera™ Vascular Covered Stent to treat arteriovenous fistula (AVF) stenoses in a real-world hemodialysis patient population.
Materials And Methods: One hundred AVF patients were prospectively enrolled at 11 clinical trial sites in the USA and treated with the covered stent after angioplasty of a clinically significant target stenosis. The primary safety outcome was freedom from any adverse event that suggests the involvement of the AV access circuit evaluated at 30 days.
J Ultrasound Med
January 2025
Department of Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Objectives: To evaluate the role of shear wave elastography (SWE) in distinguishing acute from subacute thrombi in thrombosed arteriovenous fistulas (AVFs) and explore the relationship between thrombus stiffness and outcomes of balloon angioplasty.
Materials And Methods: This retrospective study included 44 dialysis patients with thrombosed AVFs from June 2022 to June 2024. Patients underwent Doppler ultrasound and SWE to assess thrombus age, followed by balloon angioplasty.
J Am Coll Cardiol
January 2025
Division of Cardiovascular Medicine, and Sulpizio Cardiovascular Institute, University of California-San Diego, La Jolla, California, USA. Electronic address:
J Neurointerv Surg
January 2025
Department of Cerebrovascular Disease, Zhengzhou University People's Hospital, Henan Provincial People's Hospital; Henan Provincial Cerebrovascular Interventional Innovation Engineering Technology Research Center, Henan International Joint Laboratory of Cerebrovascular Disease, Zhengzhou, Henan, China
Objective: This study aimed to examine the effect of drug-coated balloons (DCBs) on vascular luminal dilatational remodeling (VLDR) following simple balloon angioplasty.
Methods: A retrospective cohort study was conducted using data from patients diagnosed with intracranial atherosclerotic stenosis (ICAS), who were treated exclusively with balloon angioplasty at Henan Provincial People's Hospital between June 2019 and April 2023. Inverse probability weighting (IPW) was used to create balanced cohorts of patients who underwent drug-coated balloon angioplasty (DCBA) and plain old balloon angioplasty (POBA).
Catheter Cardiovasc Interv
January 2025
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: Evidence regarding drug-coated balloon (DCB)-only angioplasty in de novo lesions of large vessels is still limited and mainly focused on paclitaxel-coated balloon. We aimed to analyze the safety and efficacy of sirolimus-coated balloon (SCB)-only angioplasty in de novo lesions in large vessels compared to drug-eluting stent (DES).
Methods: In this retrospective, dual-center, case-control study, we enrolled all consecutive patients treated between January 2022 and January 2024 with SCB-only angioplasty in de novo lesion in large vessel (> 2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!